+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Brazil Pharma and Healthcare Sector Report 2018-2022 - Product Image

Brazil Pharma and Healthcare Sector Report 2018-2022

  • ID: 4757347
  • Report
  • Region: Brazil
  • 100 pages
  • EMIS, An ISI Emerging Markets Group Company
1 of 4

FEATURED COMPANIES

  • EMS SA
  • Eurofarma Laboratorios SA
  • Rede D’Or Sao Luiz SA
  • MORE
This report provides a complete and detailed analysis of the healthcare and pharmaceutical sector for Brazil . The publisher presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:
  • Understand the key elements at play in the healthcare and pharmaceutical sector in Brazil
  • Access forecasts for growth in the sector
  • View key data on healthcare spending and health insurance in Brazil
  • Crystallise the forces both driving and restraining this sector in Brazil
  • Build a complete perspective on sector trade, investment and employment
  • Understand the competitive landscape and who the major players are
  • View M&A activity and major deals
  • Gain an understanding of the regulatory environment for the sector in Brazil
  • Build a clear picture of trends and issues for sub-sectors (medical institutions, pharmaceuticals manufacturing and distribution channels).
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • EMS SA
  • Eurofarma Laboratorios SA
  • Rede D’Or Sao Luiz SA
  • MORE
1 EXECUTIVE SUMMARY
  • Sector in Numbers
  • Sector Overview
  • Sector Snapshot
  • Driving Forces
  • Restraining Forces
2 SECTOR OUTLOOK
  • Macroeconomic Outlook
  • Economic Sentiment
  • Sector Outlook
3 SECTOR IN FOCUS
  • Main Economic Indicators
  • Main Sector Indicators
  • Demographic Trends in the Americas
  • Health Profile
  • Global Positioning
  • Foreign Direct Investment
  • Main Investment Projects
  • Employment
  • Number of Enterprises
4 COMPETITIVE LANDSCAPE
  • Timeline Brazil Pharma & Healthcare
  • Highlights
  • Market Shares
  • Top Companies
  • Top M&A Deals
  • M&A Activity, 2017-Q3 2018
5 COMPANIES IN FOCUS
  • Ache Laboratorios Farmaceuticos SA
  • EMS SA
  • Eurofarma Laboratorios SA
  • Rede D’Or Sao Luiz SA
  • Diagnosticos da America SA
6 REGULATORY ENVIRONMENT
  • Key Bodies
  • Unified Health System
  • Government Policy
  • Drug Prices
  • Tax Burden on Drugs
  • Productive Development Partnerships
  • Popular Pharmacy Programme
7 PHARMACEUTICALS
  • Highlights
  • Main Events
  • Production
  • Sales
  • Institutional Drug Market
  • External Trade
  • Imports
  • Exports
8 HEALTHCARE
  • Highlights
  • Main Events
  • Health Infrastructure
  • Focus Point - Top 10 States by Number of Hospitals
  • Medical Doctors
  • Focus Point - Top 10 States by Number of
  • Medical Doctors
  • Public Health Expenditure
  • Focus Point - Public Health Expenditure per
  • Capita by State
  • Private Health Insurance
  • Focus Point - Penetration Rate of Medical and
  • Hospital Assistance Plans by State
  • Focus Point - Penetration Rate of Dental Care
  • Only Plans by State
9 RETAIL CHANNELS
  • Retail Channels
  • Focus Point - Retail Drug Sales Value
  • Drugstore Chains Ranking
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • EMS SA
  • Eurofarma Laboratorios SA
  • Rede D’Or Sao Luiz SA
  • MORE
Brazil’s 208mn population has given rise to a sizeable healthcare sector and to the sixth largest pharmaceutical market in the world. In 2017, retail drug sales, based on pharmacy purchase price (PPP), rose by 11.7% y/y to BRL 56.8bn, supported by strong demand for both innovative patented drugs and generics. Yet, volume-wise the market decelerated, growing by 6.1% y/y, the slowest pace in a decade, as a result of the high unemployment, the decreasing disposable income of the population and the reduction of the number of private health insurance plan holders. As a result, the domestic pharmaceutical production continued to decline, propelling further the ongoing restructuring of the industry. This scenario has also put increasing pressures on the chronically underfunded public health system, outlining the need of an urgent reform of the national health model.
Note: Product cover images may vary from those shown
5 of 4
  • Ache Laboratorios Farmaceuticos SA
  • EMS SA
  • Eurofarma Laboratorios SA
  • Rede D’Or Sao Luiz SA
  • Diagnosticos da America SA
Note: Product cover images may vary from those shown
Adroll
adroll